Plain-English translation of NCT07285239 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called belantamab mafodotin, when combined with three standard myeloma drugs (, , and ), works better than another treatment called daratumumab combined with the same three standard drugs. The goal is to see which combination helps patients achieve deeper remission—meaning fewer or no detectable cancer cells—and keeps the disease under control longer.
Multiple myeloma is a serious blood cancer, and doctors want to find the best treatment options for patients who cannot or choose not to have a stem cell transplant. This medication works by targeting cancer cells in a new way, and researchers want to know if it can help patients achieve better and longer-lasting responses compared to current treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two treatment combinations, both given as outpatient infusions over 28-day cycles. Throughout the study, you will have regular blood tests, bone marrow biopsies at specific timepoints to measure how well the cancer is responding, and visits with your doctor to monitor how you are tolerating the treatment. You will continue treatment for as long as the disease remains under control and you are tolerating it well, with follow-up visits occurring every 6 months initially, then annually.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States